Domainex has purchased over £1 million worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays. The company says the equipment will allow Domainex to increase its capacity and throughput, supporting its ongoing growth.
Official comments
Dr Tom Mander, CEO of Domainex, said: “We have an ambitious capital investment programme planned for 2022 which we are funding from our profits. We are seeing strong demand for our range of bioanalytical chemistry services. This significant capital investment will give our analytical chemistry team access to state-of-the-art technologies to provide high-quality data to our clients. This expansion will allow us to continue to fully support our integrated drug discovery programmes. We have used Waters equipment for many years and have always been pleased with the quality of their products and the first class support they provide us.”
Joe Kildunne, Director for Pharmaceutical Marketing at Waters, commented: “It is a pleasure to partner with Domainex, an organisation who understands the need to provide best in class scientific solutions for their sponsors. At Waters we are passionate about providing our customers with the tools and support they need to grow their scientific capabilities and their business success.’’
